Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: N.J. Bans Microbeads; Prestige Device Sales; Direct Sellers Merge

This article was originally published in The Rose Sheet

Executive Summary

New Jersey becomes the second state that will prohibit the production and sale of microbeads, as Gov. Chris Christie signs into law a bill that closely follow’s Illinois’ industry-backed legislation. More news in brief.

You may also be interested in...



Regulatory News In Brief: House Microbeads Bill; Oregon Eyes Children’s Cosmetics; More

Rep. Frank Pallone, D-N.J., reintroduces his bill proposing a ban on personal-care products containing synthetic plastic microbeads; Oregon legislation would require ingredient reporting and reformulations from manufacturers of children’s cosmetics containing flagged chemicals. More regulatory news.

In Brief

Expected guidance on lead in cosmetics is still under development, CFSAN says; Avon finalizes settlement with SEC over China bribery charges. More news in brief.

FTC Fines L’Occitane For “Slimming” Claims, Calls For Media “Gut Check”

FTC settles with L’Occitane and three marketers of weight-loss products and launches its “gut check” voluntary media partnership program to help prevent bogus claims. Settlements with the four marketers totaled $33 million.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019428

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel